Sign in

Research summary ·

Efficacy and tolerability of mirogabalin, pregabalin, duloxetine, and placebo in patients with type 2 diabetes mellitus and painful diabetic peripheral neuropathy: A network meta-analysis.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review looked at nerve pain caused by type 2 diabetes. It compared mirogabalin, pregabalin and duloxetine with a dummy drug. The team searched large study databases for trials. In these trials, people were put into groups by chance. The trials had 4,542 adults and ran from 2005 to 2024. Their mean age was 57.7 years. Their pain at the start was moderate.

What they found

Duloxetine 120 mg gave the largest drop in pain. Trust in this result was rated high. Mirogabalin 30 mg came next for pain relief. Pregabalin gave only a modest gain. Only mirogabalin 30 mg clearly raised the odds of a large pain drop. Pregabalin 600 mg clearly raised the odds of side effects. Weight gain and swelling were more common with pregabalin and mirogabalin. Sleepiness was seen with all of the drugs.

What it means for patients

The authors say duloxetine eased pain in the most steady way. This applies to the short trials they could find. They say its safety record for metabolism was also better than pregabalin and mirogabalin. They argue pregabalin should not be a routine first choice for this pain. Their reason is its modest gain and its high load of harms.

Why it is not certain yet

The trials in this review were short. So the abstract does not show how the drugs work over a long time. The abstract gives a trust rating only for the duloxetine result. A review can only be as good as the studies in it.

Source

Efficacy and tolerability of mirogabalin, pregabalin, duloxetine, and placebo in patients with type 2 diabetes mellitus and painful diabetic peripheral neuropathy: A network meta-analysis.

PubMed · PMID 42562184

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Type 2 diabetes publications